Research & Clinical Trials

As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.

| More

NCT01482715

A Study of Oral Rucaparib in Patients With gBRCA Ovarian Cancer, or Other Solid Tumor

Study identifier: NCT01482715
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Rucaparib (Clovis)

Eligibility:

  • Ovarian cancer associated with a gBRCA mutation that has relapsed >6 months following platinum-based prior treatment and is measurable. Two to four prior treatment regimens permitted.

Type of study:

Phase I/II single-agent. Single group assignment (all participants receive study agent).

Treatment:
Oral tablet administered daily; 21-day cycles of treatment. In Part 1, the initial dose level is 40 mg/day; doses will be escalated in subsequent patient cohorts until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. Patients enrolled in Part 2 will receive the RP2D daily for continuous 21-day treatment cycles..

Study sites:

Florida
Sarasota
Sarah Cannon Research Institute Recruiting
Contact: Heather Rieth at: hrieth@flcancer.com

Massachusetts
Boston
Dana-Farber Cancer Institute
Contact: Andrew Wolanski at: andrew_wolanski@dfci.harvard.edu

Michigan
Detroit
Karmanos Cancer Institute Recruiting
Contact: Entela Rama at: ramae@karmanos.org

Tennessee
Nashville
Sarah Cannon Research Institute Recruiting
Contact: Julie Pfrommer at: julie.pfrommer@scresearch.net

United Kingdom
London
University College London Cancer Institute Recruiting
Contact: Rebecca Kristeleit at: r.kristeleit@ucl.ac.uk

Page updated 06/10/13